Ammonium chloride, also known as NH4Cl, is a widely used compound in the medical field. It is typically used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. This article will explore the potential of NH4Cl, looking at its possible applications in medical treatments and other uses.
NH4Cl is a white, crystalline salt, with a molecular weight of 53.49 g/mol and a density of 1.527 g/cm3. It is highly soluble in water, with a solubility of 1.6 g/100 ml, and is also soluble in alcohols and other organic solvents. It is a weak acid, with a pKa of 9.25, and is readily hydrolyzed in water. It is also hygroscopic, meaning it absorbs moisture from the air.
NH4Cl is used in the medical field for a variety of purposes. It is used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. It is also used in the treatment of certain medical conditions, such as hypokalemia, hyperkalemia, and metabolic acidosis.
Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl has potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent.
Research has shown that NH4Cl may have potential applications in the treatment of cancer. In one study, NH4Cl was found to inhibit the growth of human breast cancer cells in vitro. In another study, NH4Cl was found to inhibit the growth of human liver cancer cells in vitro. The mechanism of action is not yet clear, but it is thought to involve the inhibition of cell proliferation and the induction of apoptosis.
NH4Cl has also been studied for its potential use as a wound healing agent. In one study, NH4Cl was found to improve wound healing in animal models. The mechanism of action is not yet clear, but it is thought to involve the stimulation of collagen synthesis and the promotion of angiogenesis.
NH4Cl has also been studied for its potential use as an anti-inflammatory agent. In one study, NH4Cl was found to reduce inflammation in animal models. The mechanism of action is not yet clear, but it is thought to involve the inhibition of pro-inflammatory cytokines.
NH4Cl is a widely used compound in the medical field, used as a buffer, electrolyte, preservative, and stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl may have potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent. Further research is needed to explore the potential of NH4Cl in these and other applications.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation